Govt approves higher prices for critical cancer drugs amid supply crisis

In a critical move to avert a deepening healthcare catastrophe, the Central Government of India has granted in-principle approval for price increases on four essential medicines, including the cornerstone platinum-based chemotherapy drugs, cisplatin and carboplatin. This emergency intervention, approved by the Department of Pharmaceuticals on June 7, comes as a severe nationwide shortage, driven by skyrocketing global raw material costs and rigid price controls, paralyzes cancer treatment across the country. The National Pharmaceutical Pricing Authority (NPPA) is now tasked with determining the precise extent of these hikes, which could range from 10% to 50% from previous fixations, potentially impacting thousands of cancer patients already battling a costly disease. At the heart of this crisis is the relentless surge in raw platinum prices, a key Active Pharmaceutical Ingredient (API) for cisplatin and carboplatin, which has seen an estimated 225% spike in recent years, with a staggering 100% jump in just the last six months alone. Geopolitical tensions, particularly the West Asia crisis and disruptions to the Strait of Hormuz, have exacerbated supply chain volatility, making it financially unviable for domestic pharmaceutical industry (India) manufacturers to produce these National List of Essential Medicines (NLEM) under existing Drugs (Prices Control) Order (DPCO) 2013 caps. Many producers had either scaled back or entirely halted manufacturing, creating dire treatment delays at premier oncology centers and forcing doctors to ration vital doses. The government's approval, invoked under the extraordinary powers of Para 19 of DPCO 2013, underscores the severity of the supply chain crisis and the lack of viable medical substitutes for these foundational cancer therapies. The NPPA is expected to finalize the revised prices within days, aiming to incentivize manufacturers to resume full production, yet the move triggers significant concerns regarding the drugs' affordability for an already vulnerable patient population. The delicate balancing act between ensuring drug availability and maintaining affordability will define the immediate future of cancer care in India.